



# Rishi Vansh

All India Institute of  
Medical Science Rishikesh

**AIIMS**  
Department of Pediatrics  
Genetic division

Volume 5  
Issue 50, July 2024


H4

H2A

H2B

H3

H1



### From the desk of Editor

The genetic division of the Pediatric Department publishes a monthly newsletter for all Medical Professionals. The newsletter is related to genealogical parlance and is a deliberate attempt to enhance awareness of genetic disorders with recent updates.

## Editorial Board

**Chief Patron**

Prof. Meenu Singh  
(Executive Director)

**Patron**  
Prof. Jaya Chaturvedi  
(Dean academic)

**President**

Prof. N. K. Bhat  
(HOD)

**Editor**

Dr. Prashant Kumar Verma

**Asso. Editor**

Dr. Manisha Naithani

**Assi. Editors**

Dr. Vinod Kumar

Dr. Pooja Bhadoria

Author: Prashant Kumar Verma<sup>1</sup>,


<sup>1</sup> Department of Pediatrics, Chairperson of Medical Genetic division,  
AIIMS Rishikesh, Uttarakhand, India

DOI: 10.13140/RG.2.2.29603.05920


Reviewer: Dr. Raksha Ranjan,

<sup>1</sup> Department of Pediatrics, AIIMS Bathinda, Punjab, India

## Progeroid Syndromes Like (PSL)-III / LAMIN A/C related disorders/ Mandibuloacral dysplasia type A lipodystrophy (MADA)



### Acro-osteolysis



- Acro: tip/end; and osteolysis: bone resorption
- Radiologically diagnosed as distal phalangeal and clavicle osteolysis
- Etiologies: congenital or acquired (external or internal causes)
- Swelling (Clubbing) or atrophic changes in adjacent tissues
- Classification: (A) Based on radiological changes noticed in the bone (three types): terminal tuft (longitudinal type), midshaft (transverse type), and both together (longitudinal & transverse bone reabsorption); (B) Anatomical involvement: Localize versus systemic, single digit versus multiple, upper limb versus lower limb, or both

### Insight:

1. Why is it called mandibuloacral dysplasia?
2. What are the principal differences between MADA and Hutchinson-Gilford progeria?
3. How would you counsel the family for Case IV: 2?
4. What is the possible explanation for acro-osteolysis?
5. How would you approach a case of acro-osteolysis?

### Plausible tenets:

- **Osteolysis:** over activity of osteoclasts leads to the destruction of bone matrix over time.
- **Osteolysis with Laminopathies:** Probably by significantly higher levels (approximately 4.7-fold) of the active enzyme forms of **MMP9 (metalloproteinases)**.
- OMIM search shows 37 entries by “osteolysis” with clinical synopsis, **33 entries** with “acro-osteolysis OR acroosteolysis,” and **seven entries besides laminopathies** (Mandibuloacral Dysplasia with Type A Lipodystrophy, Restrictive Dermopathy 2, MADA, Lipodystrophy, Familial Partial, Type 2; FPLD2, & Hutchinson-Gilford progeria) with “**clavicle AND acro-osteolysis OR acroosteolysis**”.

### Syndromes with clavicle anomaly AND acro-osteolysis OR acroosteolysis:

No.	Phenotype	MIM No.	Gene / Function / MOI	Additional key findings
1.	Pycnodysostosis [from Greek: πυκνός (puknos) meaning "dense", Dys ("defective"), and ostosis ("condition of the bone")]	#265800	Cathepsin K gene (CTSK)/ cysteine proteinases in osteoclast cells/ <b>AR</b>	Growth hormone therapy in selected cases
2.	<b>Mandibuloacral Dysplasia With Type B Lipodystrophy; MADB</b>	#608612	ZMPSTE24/ an endoprotease, conversion of prelamin A/ <b>AR</b>	Renal involvement, skin nodules
3.	Multicentric Carpotarsal Osteolysis Syndrome; MCTO	#166300	MAFB/ dual function transcription factors/ <b>AD</b>	CKD, JRA like radiological pictures
4.	Hypertrophic Osteoarthropathy, Primary, Autosomal Recessive, 1; PHOAR1	#259100	HPGD/ 15-hydroxyprostaglandin dehydrogenase (degradation of PGs) / <b>AR</b>	Marfanoid habitus, furrowing of the forehead, large clavicle
5.	Osteosclerotic Metaphyseal Dysplasia; OSMD	#615198	LRRK1/ maturation of osteoclasts/ <b>AR</b>	Osteosclerosis of clavicle & other bones, raised AST
6.	Cleidocranial Dysplasia 1; CLCD1	#119600	RUNX2/ Transcription factor, maturation of osteoblasts/ <b>AD</b>	Not a true acro-osteolysis
7.	Melnick-Needles Syndrome; MNS	#309350	FLNA/ interacting filaments at various level/ <b>XLD</b>	Short clavicles, cleft palate, CHD

- Other more specific head-toe findings with MADA **besides common laminopathies phenotypes include** wormian bones, wide cranial sutures, micrognathia, mandibular hypoplasia, progressive osteolysis of the distal phalanges and clavicles (acroosteolysis), hypoplastic clavicles, **hypomorphic progeroid phenotypes**, and restricted joint mobility.
- Overlapping phenotypic syndromes: Hajdu-Cheney syndrome (**NOTCH2**), Hallermann-Streiff syndrome (? ), Gottron type acrogeria (? ), Werner syndrome (**RECQL2**)

- **Matrix MetalloProteinase 9(MMP9), Gelatinase B (GELB):** a zinc metalloprotease, helps in leukocyte migration besides having proteolytic enzymes activities against extracellular matrix proteins (PubMed: 1480034, 2551898, and 12879005), like bone matrix resorption by cleavage of various collagen fibers.
- Phenotype: **Metaphyseal anadysplasia 2 (Ana = prefix meaning return), (MOI-AR)**, an early-onset metaphyseal dysplasia with spontaneous regression with age: infantile genu varum (bowlegs) with scoliosis, and metaphyseal fraying of the distal femurs and distal tibias. **Post-toddlerhood, all abnormalities start to resolve themselves without affecting the final height.**

**Counsel the family for antenatal diagnosis of case IV: 2-** At 29 weeks, without abnormalities in all previous antenatal investigations, we need to re-evaluate for specific anomalies as directed by an expert. Phenotyping of the proband and all other affected family members can help to reach a clinical impression. Possibilities for disease in the fetus cannot be discussed during counseling without a confirmed diagnosis; it can significantly affect fetal and maternal health. Additionally, discussion on possibilities without evidence can have consultation irregularities and legal implications.

### Thought Riveting:

- ❏ *Is aging a slowly adaptive cellular behavior against the surrounding environment of the cell?*
- ❏ *How could aging be reversed in a specific environment, specifically in the absence of mutagenic or extreme environmental situations?*
- ❏ *Can specific viral infections accelerate or deaccelerate the aging process?*
- ❏ *What is the effect of a high MMP9 levels on the cellular level in other tissues? Is there any role for a MMP9 inhibitor (CAS number 1177749-58-4) or Mangiferin?*
- ❏ *Can augmentation of the ZMPSTE24 protein rescue the LMNA-associated phenotype?*